Tag: Nova Mentis - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Nova Mentis Begins Enrollment in North American Autism Study

Nova Mentis Begins Enrollment in North American Autism Study

Post published:March 23, 2022
Post category:Press Release

Read more about the article Nova Mentis Announces Closing of Non-Brokered Financing

Nova Mentis Announces Closing of Non-Brokered Financing

Post published:March 15, 2022
Post category:Press Release

Read more about the article Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

Post published:February 16, 2022
Post category:Press Release

Read more about the article Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

Post published:January 12, 2022
Post category:Press Release

Read more about the article Nova Mentis Files Genetic Neuroinflammatory Disease Patent

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

Post published:November 9, 2021
Post category:Press Release

Read more about the article U.S. FDA Approves Nova Mentis Orphan Drug Application

U.S. FDA Approves Nova Mentis Orphan Drug Application

Post published:November 2, 2021
Post category:Press Release

Read more about the article Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome

Post published:October 26, 2021
Post category:Press Release

Read more about the article Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Post published:October 19, 2021
Post category:Press Release

Read more about the article Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Post published:September 14, 2021
Post category:Press Release

Read more about the article Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Post published:September 7, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.